市場調查報告書
商品編碼
1262674
臨床前 CRO 市場——按服務(生物分析和 DMPK 試驗、毒理學試驗)、按最終用戶(生物製藥公司、政府和學術機構、醫療器械公司)、按地區和全球預測,2023-2032 年Preclinical CRO Market - By Service (Bioanalysis & DMPK Studies, Toxicology Testing), By End-use (Biopharmaceutical Companies, Government & Academic Institutes, Medical Device Companies), By Region & Global Forecast, 2023 - 2032 |
臨床前 CRO 市場將在 2032 年穩步增長,因為慢性病的增加和對有效治療的需求不斷增加預計會推動臨床前研究中藥物使用的增加。
此外,生物技術和製藥公司通常選擇外包來滿足他們在臨床前試驗中的醫療需求,從而加快整個過程。 為此,進入臨床前階段的藥物數量顯著增加。
總體而言,臨床前 CRO 市場在最終用途、服務和地域方面存在分歧。
在服務領域,“其他”子領域預計在估計期內將保持超過 7% 的複合年增長率的穩定增長率。 臨床前CRO市場的其他服務包括生物利用度研究、生物等效性研究、藥物相互作用研究服務等。
臨床前 CRO 市場根據最終用途細分為政府/學術機構、生物製藥公司、醫療設備公司等。 其中,政府和學術機構部門將在 2022 年佔據超過 14.5% 的市場份額。 這種增長主要歸因於委託給學術機構的研究和調查活動數量的增加。 學術機構和政府也正在提供臨床前診斷和治療的途徑,這將推動未來臨床前 CRO 行業的發展。
按地區劃分,臨床前 CRO 市場大致分為北美、歐洲、亞洲格局、市場格局和亞太地區。 其中,亞太地區臨床前CRO市場有望在預測期內實現穩定增長。 該地區老年人口的增加,糖尿病、癌症、心髒病等慢性病患病率的增加,預計將補充市場增長。
此外,亞太地區腫瘤領域的研究藥物和正在進行的臨床前試驗的數量正在增加,這有望推動該地區臨床前 CRO 業務的規模。
另一方面,拉美地區的臨床前 CRO 市場預計在分析期內也將出現強勁增長。 該地區擁有發達的醫療保健基礎設施和成熟的監管環境。 這些因素使拉丁美洲成為臨床前研究的沃土。
在臨床前 CRO 市場運營的領先公司包括:Laboratory Corporation of America Inc.、Charles River Laboratory Inc.、Pharmaceutical Product Development. (PPD) LLC、ICON plc、Eurofins Scientific、Parexel International Corporation, Medpace, WuXi AppTec, SGS SA, Altasciences Company, Inc.
Preclinical CRO Market is slated to grow at a robust rate through 2032 owing to the increasing usage of drugs during preclinical trials given the rising cases of chronic diseases and an increasing demand for effective treatment for the same. Besides, various biotechnology and pharmaceutical companies, quite often, opt for outsourcing to attain the medical needs for preclinical validations to fasten up the whole process. This has significantly propelled the number of drugs entering the preclinical phase.
Overall, the preclinical CRO market has been bifurcated in terms of end-use, service, and region.
Within the service segment, the others subsegment is slated to grow at a steady rate of more than 7% CAGR through the estimated timeframe. The other services in the preclinical CRO market comprise bioavailability testing, bioequivalence testing, drug-interaction testing services, etc.
Based on end-use, the preclinical CRO market has been divided into government & academic institutes, biopharmaceutical companies, medical device companies, and others. Among them, the government & academic institutes segment held more than 14.5% market share in 2022. The growth can be primarily attributed to the increasing number of research and R&D activities that are outsourced to academic institutes. Besides, academic institutes and the governments are also providing diagnosis and access to treatments under preclinical trials, which is likely to propel the preclinical CRO industry growth in the upcoming time.
In the regional landscape, the preclinical CRO market has been broadly categorized into North America, Europe, LATAM, MEA, and Asia Pacific. Among them, the preclinical CRO market in the Asia Pacific region is anticipated to grow at a steady rate over the estimated timeframe. The increasing geriatric population in this region and rising cases of chronic diseases like diabetes, cancer, and cardiac diseases are anticipated to supplement the market growth.
Additionally, an increase in the number of investigational compounds and ongoing preclinical trials in oncology in Asia Pacific will boost the preclinical CRO business size in this region.
Meanwhile, the preclinical CRO market in the LATAM region is also slated to grow at a robust rate through the analysis timeframe. The healthcare infrastructure in this region is well-developed and it also boasts a well-established regulatory environment. These factors enable Latin America to be a fertile landscape to allow preclinical research to be conducted easily.
Some of the key companies operating in the preclinical CRO market are: Laboratory Corporation of America Inc., Charles River Laboratory Inc., Pharmaceutical Product Development (PPD) LLC, ICON plc, Eurofins Scientific, Parexel International Corporation, Medpace, Inc., WuXi AppTec, SGS SA, Altasciences Company, Inc.